{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:14:18Z","timestamp":1789013658946,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"am","delay-in-days":405,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T20:49:34Z","timestamp":1564087774000},"page":"113-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recommandations du France Intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) pour l\u2019examen des mutations du domaine kinase de BCR-ABL1\u00a0dans la leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"107","author":[{"given":"Jean-Michel","family":"Cayuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Chomel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dulucq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre-Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Etancelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Nibourel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2019.05.011_bib0315","first-page":"65","article-title":"Recommandations du groupe FI-LMC pour la prise en charge des patients pr\u00e9sentant des mutations du domaine tyrosine kinase de BCR-ABL dans les h\u00e9mopathies \u00e0 chromosome Philadelphie","volume":"16","author":"Preudhomme","year":"2010","journal-title":"Hematologie"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.bulcan.2019.05.011_bib0325","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"7647","key":"10.1016\/j.bulcan.2019.05.011_bib0330","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001\u00a0enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0335","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0340","series-title":"National comprehensive cancer network guidelines chronic myeloid leukemia","author":"Radich","year":"2018"},{"issue":"12","key":"10.1016\/j.bulcan.2019.05.011_bib0345","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0350","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol Detect Quantif"},{"issue":"1","key":"10.1016\/j.bulcan.2019.05.011_bib0355","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18\u00a0years","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.bulcan.2019.05.011_bib0360","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","article-title":"Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4\u00a0study","volume":"124","author":"Millot","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2019.05.011_bib0365","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0370","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2019.05.011_bib0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.bulcan.2019.05.011_bib0380","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.05.011_bib0385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bulcan.2019.05.011_bib0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adrian","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.05.011_bib0395","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0400","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bulcan.2019.05.011_bib0405","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1\u00a0allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0410","series-title":"Asciminib, a specific allosteric BCR-ABL1\u00a0inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1\u00a0trial","first-page":"792","author":"Rea","year":"2018"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0415","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1007\/s12032-011-0092-9","article-title":"Characterization of ABL exon 7\u00a0deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia","volume":"29","author":"Meggyesi","year":"2012","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0420","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bulcan.2019.05.011_bib0425","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0430","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1\u00a0compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0435","series-title":"Compound BCR-ABL1\u00a0kinase domain mutants: prevalence spectrum and correlation with tyrosine kinase inhibitor resistance in a prospective series of Philadelphia Chromosome-Positive leukemia patients analyzed by next generation sequencing","first-page":"789","author":"Soverini","year":"2018"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0440","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1\u00a0compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0445","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1\u00a0are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2019.05.011_bib0450","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2019.05.011_bib0455","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2019.05.011_bib0460","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bulcan.2019.05.011_bib0465","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0470","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bulcan.2019.05.011_bib0475","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0480","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bulcan.2019.05.011_bib0485","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2\u00a0PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2019.05.011_bib0490","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2014","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.bulcan.2019.05.011_bib0495","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2019.05.011_bib0500","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1\u00a0mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bulcan.2019.05.011_bib0505","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0510","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18\u00a0imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.05.011_bib0515","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"10.1016\/j.bulcan.2019.05.011_bib0520","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2\u00a0trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.bulcan.2019.05.011_bib0525","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.bulcan.2019.05.011_bib0530","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2019.05.011_bib0535","article-title":"Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients","volume":"94","author":"Hochhaus","year":"2015","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.bulcan.2019.05.011_bib0540","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0545","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89\u00a0imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bulcan.2019.05.011_bib0550","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2019.05.011_bib0555","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bulcan.2019.05.011_bib0560","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0565","series-title":"International control round for deep sequencing analysis of BCR-ABL kinase domain mutations in 11\u00a0laboratories from 7\u00a0European countries","author":"Ernst","year":"2015"},{"issue":"9","key":"10.1016\/j.bulcan.2019.05.011_bib0570","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2019.05.011_bib0575","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1\u00a0mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0580","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1\u00a0at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2019.05.011_bib0585","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2014-05-573485","article-title":"Many BCR-ABL1\u00a0compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination","volume":"124","author":"Parker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.05.011_bib0590","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.leukres.2018.04.008","article-title":"The rising prevalence of chronic myeloid leukemia in France","volume":"69","author":"Delord","year":"2018","journal-title":"Leukemia Res"},{"issue":"12","key":"10.1016\/j.bulcan.2019.05.011_bib0595","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2019.05.011_bib0600","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1373\/clinchem.2009.133843","article-title":"Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment","volume":"56","author":"Gruber","year":"2010","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.bulcan.2019.05.011_bib0605","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.bulcan.2019.05.011_bib0610","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1039\/c1lc20128j","article-title":"Quantitative and sensitive detection of rare mutations using droplet-based microfluidics","volume":"11","author":"Pekin","year":"2011","journal-title":"Lab Chip"},{"issue":"4","key":"10.1016\/j.bulcan.2019.05.011_bib0615","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bulcan.2019.05.011_bib0310","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119302590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119302590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:31:17Z","timestamp":1757791877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119302590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007455119302590"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.05.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du France Intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) pour l\u2019examen des mutations du domaine kinase de BCR-ABL1\u00a0dans la leuc\u00e9mie my\u00e9lo\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}